Last reviewed · How we verify
Valsartan, Valsartan HCT — Competitive Intelligence Brief
marketed
Small molecule
Live · refreshed every 30 min
Target snapshot
Valsartan, Valsartan HCT (Valsartan, Valsartan HCT) — Novartis.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Valsartan, Valsartan HCT TARGET | Valsartan, Valsartan HCT | Novartis | marketed |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Valsartan, Valsartan HCT CI watch — RSS
- Valsartan, Valsartan HCT CI watch — Atom
- Valsartan, Valsartan HCT CI watch — JSON
- Valsartan, Valsartan HCT alone — RSS
Cite this brief
Drug Landscape (2026). Valsartan, Valsartan HCT — Competitive Intelligence Brief. https://druglandscape.com/ci/valsartan-valsartan-hct. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab